You are here

News story

Any general news stories or articles in the media we believe are of interest to you

Dasatinib Commonly Induces Lymphocytosis in CML Patients

sandy craine's picture
Submitted by sandy craine on Thu, 31/03/2016 - 3:35pm

News | March 29, 2016 | Chronic Myeloid Leukaemia, Cancer Complications, Haematologic Malignancies, Leukaemia & Lymphoma
By Dave Levitan

Patients with chronic myeloid leukemia (CML) who are treated with the tyrosine kinase inhibitor (TKI) dasatinib commonly experience lymphocytosis, and the condition is associated with higher response rates and increased survival in patients who are refractory or intolerant of imatinib, according to a new study.

International CML Foundation- November 2015 Newsletter

sandy craine's picture
Submitted by sandy craine on Mon, 21/12/2015 - 5:56pm

The International CML Foundation (iCMLf) is a Foundation established by a group of leading hematologists with a strong interest in CML. The mission of the iCMLf is to improve the outcomes for patients with CML globally. The Foundation is registered as a charitable organisation in England and Wales but its charter is global. Its aims are to foster and coordinate global clinical and research collaborations and to improve clinical practice and disease monitoring in CML, especially in emerging economic regions.

CMLSg's comment on FAD: 1st line use of dasatinib, nilotinib, imatinib. CMLSg will not appeal this FAD.

sandy craine's picture
Submitted by sandy craine on Fri, 23/03/2012 - 10:24am
In the circumstances we feel we have done all we can and that an appeal is not a positive option for us.

In the circumstances we feel we have done all we can and that an appeal is not a positive option for us.

BBC News regarding NICE appraisal of dasatinib and nilotinib- plus TV3 interview regarding tasigna

sandy craine's picture
Submitted by sandy craine on Wed, 06/01/2010 - 11:40am
BBC News regarding NICE appraisal of dasatinib and nilotinib http://news.bbc.co.uk/1/hi/england/london/8440877.stm

BBC News regarding NICE appraisal of dasatinib and nilotinib
http://news.bbc.co.uk/1/hi/england/london/8440877.stm

And then there was Glivec

sandy craine's picture
Submitted by sandy craine on Tue, 19/09/2006 - 4:19pm
A race against time... Patients' clamour for Gleevec began in spring 1999, as soon as the results of the first tests on CML patients spread. Thanks to the Internet they were aware of the drug from its early stages.

A race against time... Patients' clamour for Gleevec began in spring 1999, as soon as the results of the first tests on CML patients spread. Thanks to the Internet they were aware of the drug from its early stages.

Pages